Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
about
Alterations in Mitochondrial Quality Control in Alzheimer's DiseaseAmyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer's diseaseNon-microtubular localizations of microtubule-associated protein 6 (MAP6)Efficient computation of transfer free energies of amino acids in beta-barrel membrane proteins.Outer membrane β-barrel protein folding is physically controlled by periplasmic lipid head groups and BamA.The Armc10/SVH gene: genome context, regulation of mitochondrial dynamics and protection against Aβ-induced mitochondrial fragmentationMitochondrial Aspects of Synaptic Dysfunction in Alzheimer's Disease.Mitochondrial VDAC1: A Key Gatekeeper as Potential Therapeutic TargetThe Voltage-dependent Anion Channel 1 Mediates Amyloid β Toxicity and Represents a Potential Target for Alzheimer Disease Therapy.Proteomic analysis of lymphoblastoid cells from Nasu-Hakola patients: a step forward in our understanding of this neurodegenerative disorder.Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease?Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damageRNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity.Cyclophilin D deficiency rescues Aβ-impaired PKA/CREB signaling and alleviates synaptic degeneration.Reduced VDAC1 protects against Alzheimer's disease, mitochondria, and synaptic deficiencies.Abnormal interaction of oligomeric amyloid-β with phosphorylated tau: implications to synaptic dysfunction and neuronal damage.Garrison Institute on Aging: A New Hope for Elderly Individuals and Patients with Alzheimer's Disease.Mitochondrial dysfunction in psychiatric and neurological diseases: cause(s), consequence(s), and implications of antioxidant therapy.Oestrogens as modulators of neuronal signalosomes and brain lipid homeostasis related to protection against neurodegeneration.Deconstructing mitochondrial dysfunction in Alzheimer disease.S-Nitrosylation in Alzheimer's disease.Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer's disease.Mitochondrial cholesterol: mechanisms of import and effects on mitochondrial function.The mitochondrial epigenome: a role in Alzheimer's disease?The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders.Alzheimer's Disease: From Mitochondrial Perturbations to Mitochondrial Medicine.Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.A disease with a sweet tooth: exploring the Warburg effect in Alzheimer's disease.Biological and biophysics aspects of metformin-induced effects: cortex mitochondrial dysfunction and promotion of toxic amyloid pre-fibrillar aggregates.Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics.Hexokinase I N-terminal based peptide prevents the VDAC1-SOD1 G93A interaction and re-establishes ALS cell viability.NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease.Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease.Plasmalemmal VDAC-1 corroborated as amyloid Aß-receptor.Diabesity and Brain Energy Metabolism: The Case of Alzheimer's Disease.Global analysis of ginsenoside Rg1 protective effects in β-amyloid-treated neuronal cellsNear infrared light decreases synaptic vulnerability to amyloid beta oligomers.Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies.
P2860
Q26768215-C364F349-EDDF-4874-B41F-5B29E5F85878Q27012950-C0BE3DCE-578A-4A6D-A059-AD42E7A19AACQ28542788-9F8155B6-E6B3-46F1-83A3-FC3BA719D28AQ30152669-833142CD-2D78-4A6F-BB7F-76D0D84E2518Q30153415-D8A3EBFB-7816-4358-A56C-A8A59DC820A4Q30798412-1A404FBA-4639-4608-9211-D167956E1074Q33585950-AF10673D-F3A3-4AFC-89A3-C66DD343156DQ33854939-0E614B69-9C4C-4B14-A970-E21A24B833D2Q34500757-5FA695C9-EE6A-4F0D-BB29-12E88F52D49FQ34623948-F26791EA-7EA6-450D-B210-CF5BF2FE3127Q34626547-FB278108-D520-4665-BEFC-0D7546E6F6D5Q36456888-F1F5A67A-9A34-4AA6-98BB-8DCE5ED529ECQ37302845-181893DF-A2F6-4837-9A01-015E881FE312Q37315215-354A3490-1C4F-43A6-AEA4-B607DB5E0E4AQ37404781-245F11B8-1761-41AF-A90D-633802FABF12Q37586163-8E706C4A-3F79-4C57-A761-A87745303D29Q37618817-93CFB8EE-380A-4342-BFA6-1FF4F745DB84Q37690598-427ECDED-A2C1-4E82-8E3C-E72ACBD0901DQ38086474-95265480-C7FD-4330-8458-923BD5AF58CDQ38116551-628A6E08-447D-49D2-81DB-2DEF20E6425FQ38120531-14F70AA4-E4CE-48FB-85D8-524E31ACFBADQ38199001-32B58533-3851-44CC-A214-5E243CF7F450Q38217857-08C379F9-E6E9-446E-BCDC-7B19166D9250Q38271508-54F8B5AB-543F-47D4-919F-388CE14C1B7FQ38296765-ECBB0CF5-D5D7-4FDA-98F7-FDFE0DE0B2D5Q38574561-1117C184-BF1D-41D3-BC2D-14E0DE91D227Q38872085-2B3716CA-653A-44E0-86B5-6039D9F5C193Q38962796-0D77BF3A-B3D8-4411-ABBE-346579A999A8Q39185516-570D2F8C-B49C-46C0-89FE-794CD4216280Q41152081-8202E717-71DA-440F-B5C6-C5ACA36CEC06Q41173095-362E4E67-B284-4B6E-B4C0-5D7A25F97DC7Q41380791-673F9EBB-D804-4C0E-AFF0-3C37265452D3Q41427586-C116B127-D15A-45F2-B74C-79EABE8937A6Q41444056-E870C89A-0B9B-4A8C-B12A-6CE80EFAE2AFQ41574564-349B9828-AD51-4354-81D7-C55EDEF42792Q41591744-DBC22923-B731-4376-8176-9C0872343145Q41995767-4B860AF6-6F09-4AC4-8BD3-E62FAAD14488Q42108536-407C1DC0-65D2-4010-813C-DDB7567833EEQ43573798-77717F1F-2257-4B66-A857-C24FB0C1F918Q46240783-478105EF-BD3B-45E7-9AD1-3D0924838A88
P2860
Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Abnormal interaction of VDAC1 ...... nction in Alzheimer's disease.
@ast
Abnormal interaction of VDAC1 ...... nction in Alzheimer's disease.
@en
type
label
Abnormal interaction of VDAC1 ...... nction in Alzheimer's disease.
@ast
Abnormal interaction of VDAC1 ...... nction in Alzheimer's disease.
@en
prefLabel
Abnormal interaction of VDAC1 ...... nction in Alzheimer's disease.
@ast
Abnormal interaction of VDAC1 ...... nction in Alzheimer's disease.
@en
P2860
P356
P1476
Abnormal interaction of VDAC1 ...... nction in Alzheimer's disease.
@en
P2093
Maria Manczak
P Hemachandra Reddy
P2860
P304
P356
10.1093/HMG/DDS360
P577
2012-08-27T00:00:00Z